Transgenic expression of aflatoxin aldehyde reductase (AKR7A1) modulates aflatoxin B1 metabolism but not hepatic carcinogenesis in the rat

Toxicological Sciences

Volumn 109, Issue 1, 2009, Pages 41-49

  Roebuck, Bill D ^a   Johnson, Denise N ^b   Sutter, Carrie Hayes ^d   Egner, Patricia A ^b   Scholl, Peter F ^b,c   Friesen, Marlin D ^b   Baumgartner, Karen J ^a   Ware, Nicholas M ^a   Bodreddigari, Sridevi ^d   Groopman, John D ^b   Kensler, Thomas W ^b   Sutter, Thomas R ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d UNIVERSITY OF MEMPHIS   (United States)

Author keywords

Aflatoxin; Aldo keto reductase; Chemoprevention, hepatic carcinogenesis; Hepatotoxicity; Transgenic rat

Indexed keywords

AFLATOXIN ALDEHYDE REDUCTASE 7A1; AFLATOXIN B1; ALCOHOL; ALDEHYDE REDUCTASE; GLUTATHIONE TRANSFERASE; UNCLASSIFIED DRUG;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; CYTOSOL; DETOXIFICATION; ENZYME ACTIVITY; ENZYME SPECIFICITY; LIVER CANCER; LIVER TOXICITY; METABOLITE; NONHUMAN; PRECANCER; RAT; URINARY EXCRETION;

AFLATOXIN B1; ALCOHOLS; ALDEHYDE REDUCTASE; ALDEHYDES; ANALYSIS OF VARIANCE; ANIMALS; ANIMALS, GENETICALLY MODIFIED; CARCINOGENS; DNA ADDUCTS; LIVER; LIVER NEOPLASMS; METABOLIC DETOXICATION, DRUG; PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; RATS, TRANSGENIC;

ANIMALIA; RATTUS;

EID: 65549160528     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfp003     Document Type: Article

References (41)

1. Bodreddigari, S., Jones, L. K., Egner, P. A., Groopman, J. D., Sutter, C. H., Roebuck, B. D., Guengerich, F. P., Kensler, T. W., and Sutter, T. R. (2008). Protection against aflatoxin B1-induced cytotoxicity by expression of the cloned aflatoxin B1-aldehyde reductases rat AKR7A1 and human AKR7A3. Chem. Res. Toxicol. 21, 1134-1142.
2. Busby, W. F., and Wogan, G. N. (1984). Aflatoxins. In Chemical Carcinogens (C. E. Searle, Ed.), pp. 945-1136. American Chemical Society, Washington, D.C.
3. 1. Mol. Carcinogenesis 3, 5-8.
4. Eaton, D. L., and Bammler, T. K. (1999). Concise review of the glutathione S-transferases and their significance to toxicology. Toxicol. Sci. 49, 156-164.
5. Eaton, D. L., Ramsdell, H. S., and Neal, G. E. (1994). Biotransformation of aflatoxins. In The Toxicology of Aflatoxins: Human Health, Veterinary, and Agricultural Significance (D. L. Eaton and J. D. Groopman, Eds.), pp. 45-72. Academic Press, New York.
6. 7-guaine in human urine by high-performance liquid chromatography and isotope dilution tandem mass spectrometry. Chem. Res. Toxicol. 19, 1191-1195.
7. 1 defines a subfamily of aldo-keto reductases. Proc. Natl. Acad. Sci. U. S. A. 90, 10350-10354.
8. Fan, J., Wang, J., Bensadoun, A., Lauer, S. J., Dang, Q., Mahley, R. W., and Taylor, J. M. (1994). Overexpression of hepatic lipase in transgenic rabbits leading to a marked reduction of plasma high density lipoproteins and intermediate density lipoproteins. Proc. Natl. Acad. Sci. U. S. A. 91, 8724-8728.
9. 1 in hamster V79 cells expressing rat cytochrome P450-2B1. Carcinogenesis 20, 1121-1125.
10. Gallagher, E. P., Kunze, K. L., Stapleton, P. L., and Eaton, D. L. (1996). The kinetics of aflatoxin B1 oxidation by human cDNA - Expressed and human liver microsomal cytochromes P450 1A2 and 3A4. Toxicol. Appl. Pharmacol. 141, 595-606.
11. 1 and its interaction with histones in rat liver in vivo. Cancer Res. 40, 4343-4351.
12. Groopman, J. D., DeMatos, P., Egner, P. A., Love-hunt, A., and Kensler, T. W. (1992). Molecular dosimetry of urinary aflatoxin-N7-guanine and serum aflatoxin-albumin adducts predicts chemoprotection by 1,2-dithiole-3-thione in rats. Carcinogenesis 13, 101-106.
13. Guengerich, F. P., Arneson, K. O., Williams, K. M., Deng, Z., and Harris, T. M. (2002). Reaction of aflatoxin B1 oxidation products with lysine. Chem. Res. Toxicol. 15, 780-792.
14. Guengerich, F. P., Cai, H., McMahon, M., Hayes, J. D., Sutter, T. R., Groopman, J. D., Deng, Z., and Harris, T. M. (2001). Reduction of aflatoxin B1 dialdehyde by rat and human aldo-keto reductases. Chem. Res. Toxicol. 14, 727-737.
15. Habig, W. H., Pabst, M. J., and Jakoby, W. B. (1974). Glutathione S-transferase. The first enzymatic step in mercapturic acid formation. J. Biol. Chem. 219, 7130-7139.
16. 1 is associated with the expression of a novel aldo-keto reductase which has catalytic activity towards a cytotoxic aldehyde-containing metabolite of the toxin. Cancer Res. 53, 3887-3894.
17. Hinshelwood, A., McGarvie, G., and Ellis, E. M. (2003). Substrate specificity of mouse aldo-keto reductase AKR7A5. Chem. Biol. Interact. 144, 263-269.
18. 1-aldehyde reductase. Biochem. J. 332, 21-34.
19. 1 dialdehyde metabolites formed by aflatoxin aldehyde reductase using isotopic dilution tandem mass spectrometry. Chem. Res. Toxicol. 21, 752-760.
20. 1 exo-epoxide with DNA: Kinetic analysis of covalent binding and DNA-induced hydrolysis. Proc. Natl. Acad. Sci. U. S. A. 94, 6121-25.
21. 1 exo-8,9-oxide and rearrangement of the dihyrodiol. J. Am. Chem. Soc. 118, 8213-8220.
22. 1: Evidence for and inducible repair response. Cancer Res. 47 1993-2001.
23. 7-guanine formation, and hepatic tumorigenesis in rats fed ethoxyquin: Role of induction of glutathione S-transferases. Cancer Res. 46, 3924-3931.
24. Kensler, T. W., Gange, S. J., Egner, P. A., Dolan, P. M., Muñoz, A., Groopman, J. D., Rogers, A. E., and Roebuck, B. D. (1997). Predictive value of molecular dosimetry: Individual versus group effects of oltipraz on aflatoxin-albumin adducts and risk of liver cancer. Cancer Epidemiol. Biomarkers Prev. 6, 603-610.
25. Kensler, T. W., Groopman, J. D., Eaton, D. L., Curphey, T. J., and Roebuck, B. D. (1992). Potent inhibition of aflatoxin-induced hepatic tumorigenesis by the monofunctional enzyme inducer 1,2-dithiole-3-thione. Carcinogenesis 13, 95-100.
26. Kensler, T. W., Groopman, J. D., Sutter, T. R., Curphey, T. J., and Roebuck, B. D. (1999). Development of cancer chemopreventive agents: Oltipraz as a paradigm. Chem. Res. Toxicol. 12, 113-126.
27. Knight, L. P., Primiano, T., Groopman, J. D., Kensler, T. W., and Sutter, T. R. (1999). cDNA cloning, expression and activity of a second human aflatoxin B1-metabolizing member of the aldo-keto reductase superfamily, AKR7A3. Carcinogenesis 20, 1215-1223.
28. 1 in the rat. Toxicol. Appl. Pharmacol. 93, 442-451.
29. 1-induced hepatic toxicity as a short term screen of cancer chemopreventive dithiolethiones. Fundam. Appl. Toxicol. 32, 250-259.
30. 1-lysine adduct in serum using isotope dilution liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 19, 2203-2210.
31. Newberne, P. M. (1973). Chronic aflatoxicosis. J. Am. Vet. Med. Assoc. 163, 1262-1269.
32. 1. J. Cell. Biochem. 91, 243-249.
33. Roebuck, B. D., Curphey, T. J., Li, Y., Baumgartner, K. J., Bodreddigari, S., Yan, J., Gange, S. J., Kensler, T. W., and Sutter, T. R. (2003). Evaluation of the cancer chemopreventive potency of dithiolethione analogs of oltipraz. Carcinogenesis 24, 1919-28.
34. Roebuck, B. D., Liu, Y.-L., Rogers, A. E., Groopman, J. D., and Kensler, T. W. (1991). Protection against aflatoxin B1-induced hepatocarcinogenesis in F344 rats by 5-(2-pyrazinyl)-4-methyl-1,2-dithiole-3-thione (Oltipraz): Predictive role for short-term molecular dosimetry. Cancer Res. 51, 5501-5506.
35. Roebuck, B. D., and Maxuitenko, Y. (1994). Biochemical mechanisms and biological implications of the toxicity of aflatoxins as related to aflatoxin carcinogenesis. In The Toxicology of Aflatoxins: Human Health, Veterinary, and Agricultural Significance (D. L. Eaton and J. D. Groopman, Eds.), pp. 27-43. Academic Press, New York.
36. Sabbioni, G., Skipper, P. L., Buchi, G., and Tannenbaum, S. R. (1987). Isolation and characterization of the major serum albumin adduct formed by aflatoxin B1 in vivo in rats. Carcinogenesis 8, 819-824.
37. Smela, M. E., Currier, S. S., Bailey, E. A., and Essigmann, J. M. (2001). The chemistry and biology of aflatoxin B1: From mutational spectrometry to carcinogenesis. Carcinogenesis 22, 535-545.
38. Wogan, G. N. (1974). Naturally occurring carcinogens. In The Physiopathology of Cancer. Biology and Biochemistry (P. Shubik, Ed.), Vol. 1, pp. 64-109. Karger, Basel.
39. Wogan, G. N., Paglialunga, S., and Newberne, P. M. (1974). Carcinogenic effects of low dietary levels of aflatoxin B1 in rats. Fd Cosmet. Toxicol. 121, 681-685.
40. Yamanaka, S., Balestra, M., Ferrell, L. D., Fan, J., Arnold, K. S., Taylor, S., Taylor, J. M., and Innerarity, T. L. (1995). Apolipoprotein B mRNA-editing protein induces hepatocellular carcinoma and dysplasia in transgenic animas. Proc. Natl. Acad. Sci. U. S. A. 92, 8483-8487.
41. Yates, M. S., Kwak, M.-K., Egner, P. A., Groopman, J. D., Bodreddigari, S., Sutter, T. R., Baumgartner, K. J., Roebuck, B. D., Liby, K. T., Yore, M. M., et al. (2006). Potent protection against aflatoxin-induced tumorigenesis through induction of Nrf2-regulated pathways by the synthetic triterpenoid, 1-[2-cyano-3-,12-dioxooleana-1,9(11)-dien-28-oly]imidazole. Cancer Res. 66, 2488-2494.